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S cientific instruments are at the heartof the scientific process, from 17th-century telescopes and microscopes,
to modern particle colliders and DNA
sequencing machines. Nowadays, most
scientific instruments in biomedical research
come from commercial suppliers [1,2], and
yet, compared to the biopharmaceutical and
medical devices industries, little is known
about the interactions between scientific
instrument makers and academic researchers.
Our research suggests that this knowledge
gap is a cause for concern.
It is the norm—and usually a requirement—
that scientists mention instruments and
their suppliers in the materials and methods
sections of research articles, since their
colleagues rely on this information to repli-
cate or adapt their experiments. However,
as the production and distribution of instru-
ments have become increasingly commer-
cialized [3], there are signs that this
information is no longer sufficient. For
example, research conducted by one of us
(C.B.) revealed that some scientific instru-
ment makers preferred not to appear as co-
authors on manuscripts—even when their
employees contributed significantly to it
[1]. It was believed that a manuscript
would appear more credible if the
company’s employees did not appear as co-
authors, thus enhancing the marketing
value of their instrument.
To complement this study, we conducted
two surveys of academic researchers in the
USA and EU to gauge how they judge infor-
mation sources for scientific instruments
[preprint: 4]. The responses from almost
1,000 academic researchers revealed a
marked distrust in manuscripts co-authored
by commercial makers of scientific instru-
ments. The first survey inquired whether
academic researchers consider information
on instruments important, while the second
survey focused on the perceived reliability
of different information sources. Combined,
they provide insight into how credible
academic researchers find information on
scientific instruments in peer-reviewed
manuscripts. As Fig 1 shows, academics
discount both the importance and the relia-
bility of information on instruments in
peer-reviewed manuscripts co-authored by
scientific instrument firm employees—even
when the firm’s instrument is not
mentioned in the manuscript. When directly
comparing the reliability of information on
instruments in manuscripts authored by
someone from the mentioned instrument
firm or not, the difference was statistically
significant and substantial. The same
perceptions were evident in all scientific
fields surveyed [preprint: 4].
We argue that these perceptions create
an, as yet underappreciated, incentive for
non-disclosure and complementary tactics
by scientific instrument makers. This pattern
of incentives mirrors those that have
generated controversial practices, such as
ghostwriting and hidden sponsorship [5].
The revelations of these practices in the
biopharmaceutical industry likely fueled a
Zeitgeist of inherent distrust in firm co-
authorship by academic researchers and
scientific instrument firms alike.
From a commercial perspective, it is not
surprising that some companies circumvent
the perceived reduced credibility by not
allowing employees to be listed as
co-authors, irrespective of whether they
contributed significantly to the published
work [1]. It boosts the credibility of the
manuscript and, presumably, also the
commercial instruments employed to gener-
ate the research data. Revelations from the
biopharmaceutical and medical devices
industries have demonstrated that such
concerns are valid. For example, a range of
studies showed how commercial sponsor-
ship of academic research on drugs shaped
the likelihood of reporting results [6] and
influenced the perception of the research
[7].
Critically, non-disclosure not only
leaves readers unable to judge potential
conflicts of interests, but it also makes
replication more difficult. More trans-
parency on if and how companies were
involved in the experiments could mitigate
these risks, as could more detailed infor-
mation in materials and methods sections,
such as instrument settings and down-
stream data analysis.
In order to assess how much information
authors are asked to provide about instru-
ments, we carried out an informal analysis
of the guidelines of the 20 most cited jour-
nals, as measured by the Google Scholar h5-
index in the categories “Health & Medical
Sciences”, “Life Sciences & Earth Sciences”,
and “Chemical & Material Sciences”. Almost
none of the guidelines require the sort of
detailed information about instrument
settings and procedures required to allow
others to replicate the experiment. More-
over, with one notable exception, none of
these journals explicitly address the issue of
contributions by instrument makers
[preprint: 4]—be they financial or technical.
Only the guidelines by the American Medical
Association (AMA) require disclosing finan-
cial contribution, specifying that if an instru-
ment was provided free of charge (a 100%
discount), it should be made explicit
[preprint: 4].
To illustrate the disclosure dilemma
facing scientists, it may be useful to imagine
a situation in which an academic researcher
received a 20% discount on an instrument
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and considerable assistance from the
company with generating and analyzing
data from said instrument. The academic
publishes the results in a peer-reviewed
journal, and the manuscript is cited multiple
times. A strict interpretation of journal
guidelines would not require the scientist to
disclose either the financial benefit or the
involvement of the company in data genera-
tion and interpretation. Moreover, since
being affiliated with a commercial company
seems to influence how fellow academic
researchers value the manuscript, the
academic and the instrument maker have a
shared incentive against disclosing pertinent
facts.
Public debate and guidelines or policies
by academic journals have contributed
significantly to tackling non-disclosure
issues in pharmaceutical research [3]. More
recently, public debate on the reproducibil-
ity of the results from biomedical research
led to further changes in both norms and
journal guidelines [8,9]. We argue that there
should be equal attention to commercial
instruments that are central to scientific
research. As the scientific instrument indus-
try is increasingly dominated by large corpo-
rations and as expensive instruments have
become commonplace in academic laborato-
ries [10], the debate on reproducibility of and
transparency in research should address the
issue of how and when researchers should
disclose the involvement of instrument firms
in research. Each day that goes by without
change further undermines the transparency
that is required for reproducibility and scien-
tific progress.
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Figure 1. The reliability and importance of information sources on scientific instruments.
Illustration of how important and reliable respondents, indicated in percent on the y-axis, consider information
on scientific instruments to be in peer-reviewed publications in general and various subcategories (x-axis).
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